Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
76-90 of 4028 results
NewVac’s ovarian cancer combination meets primary endpoints in phase II trial
NewVac has met all primary endpoints in the Phase II Clinical Trial of Quisinostat, novel selective oral histone deacetylase (HDAC1) inhibitor, which the company licensed from Janssen Pharmaceutica.
Contract Research & Services > Clinical Trials > News
Zynerba starts phase 2 trial of ZYN002 in Fragile X syndrome
By PBR Staff Writer
Zynerba Pharmaceuticals has started an exploratory phase 2 clinical trial of ZYN002 cannabidiol (CBD) topical gel in children with Fragile X syndrome, genetic disorder that causes intellectual disability, behavioral and learning challenges.
Contract Research & Services > Clinical Trials > News
Incyte treats first patient in clinical trial program for ruxolitinib in GVHD
By PBR Staff Writer
Incyte has treated first patient in the clinical trial program of ruxolitinib (Jakafi) for the treatment of steroid-refractory acute graft-versus-host disease (GVHD).
Contract Research & Services > Clinical Trials > News
Alexion’s eculizumab fails to meet primary endpoint in phase 2/3 trial
Alexion Pharmaceuticals has reported results from the PROTECT Study, a Phase 2/3 registration trial of eculizumab (Soliris) for the prevention of delayed graft function (DGF) after kidney transplantation in adult recipients of a deceased donor kidney.
Contract Research & Services > Clinical Trials > News
Roche's emicizumab haemophilia drug succeeds in phase III trial
By PBR Staff Writer
A phase 3 clinical trial assessing Roche's emicizumab haemophilia drug in patients 12 years old and older met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Inovio’s Zika vaccine evokes strong immune responses in first human trial
By PBR Staff Writer
Inovio Pharmaceuticals said that its DNA-based Zika vaccine (GLS-5700) induced robust immune responses in an early-stage study in human volunteers who have not been infected with the virus.
Contract Research & Services > Clinical Trials > News
Merrimack halts breast cancer treatment trial
By PBR Staff Writer
Merrimack Pharmaceuticals has stopped a phase 2 trial of its breast cancer treatment after an analysis suggested the drug would unlikely show benefit over the comparator treatments.
Contract Research & Services > Clinical Trials > News
ViiV Healthcare starts HIV prevention study with cabotegravir
By PBR Staff Writer
ViiV Healthcare has commenced a phase III study to assess cabotegravir, a long-acting injectable integrase strand transfer inhibitor, for the prevention of HIV infection.
Contract Research & Services > Clinical Trials > News
GSK commences phase III study for triple combination asthma therapy
By PBR Staff Writer
GlaxoSmithKline (GSK) and Innoviva have started started a triple combination therapy phase III study for the treatment of asthma.
Contract Research & Services > Clinical Trials > News
Akcea Therapeutics' metabolic disorder drug succeeds in phase 3 trial
Ionis Pharmaceuticals’ subsidiary Akcea Therapeutics announced that its phase 3 COMPASS clinical trial for volanesorsen met its primary end point of significant mean reduction in triglycerides in patients with severe hypertriglyceridemia
Contract Research & Services > Clinical Trials > News
Cancer Research UK, Bicycle Therapeutics partner to trial new therapy for advanced solid tumours
Cancer Research UK, Cancer Research Technology (CRT), and Bicycle Therapeutics will collaborate to trial a first-in-class drug for cancers of high unmet need.
Contract Research & Services > Clinical Trials > News
vTv Therapeutics' TTP273 meets primary endpoint in phase 2 study in Type 2 Diabetes
vTv Therapeutics' TTP273, an oral small molecule GLP-1 receptor (GLP-1R) agonist, demonstrated a statistically significant reduction in HbA1c in a Phase 2 study for the treatment of Type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Sage Therapeutics starts phase 2 study of SAGE-217 in movement disorders
By PBR Staff Writer
Clinical-stage biopharmaceutical firm Sage Therapeutics has dosed the first patient in phase 2 proof-of-concept trial of SAGE-217 in Parkinson's disease (PD).
Contract Research & Services > Clinical Trials > News
Novartis’ ribociclib shows significant benefit in advanced breast cancer
By PBR Staff Writer
Additional analyses of a Phase 3 study, evaluating Novartis' LEE011 (ribociclib), in combination with Femara (letrozole), in patients with hormone-receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced/metastatic breast cancer demonstrated that the combination significantly increased progression-free survival (PFS) compared to letrozole alone.
Contract Research & Services > Clinical Trials > News
Valneva gets approvals to start clinical testing of lyme disease vaccine candidate
Valneva’s vaccine candidate VLA15 against Lyme disease is now moving into clinical testing (phase I) after securing approvals in the US and Europe.
Contract Research & Services > Clinical Trials > News
76-90 of 4028 results